Cargando…

Xanthine Oxidoreductase Inhibitor Use Associated With Reduced Risk of Sarcopenia and Severe Sarcopenia in Patients Undergoing Hemodialysis

BACKGROUND: Xanthine oxidoreductase (XOR) inhibition reduces reactive oxygen species (ROS) production and enhances adenosine triphosphate (ATP) synthesis. We investigated the protective effects of XOR inhibitor treatment on sarcopenia, frequently observed in patients undergoing hemodialysis (HD), in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kurajoh, Masafumi, Mori, Katsuhito, Miyabe, Mizuki, Matsufuji, Shota, Kizu, Akane, Tsujimoto, Yoshihiro, Emoto, Masanori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859856/ https://www.ncbi.nlm.nih.gov/pubmed/35198574 http://dx.doi.org/10.3389/fmed.2022.817578

Ejemplares similares

Nutritional Status Association With Sarcopenia in Patients Undergoing Maintenance Hemodialysis Assessed by Nutritional Risk Index
por: Kurajoh, Masafumi, et al.
Publicado: (2022)

Xanthine oxidoreductase activity is associated with serum uric acid and glycemic control in hemodialysis patients
por: Nakatani, Ayumi, et al.
Publicado: (2017)

Impact of diabetes on sarcopenia and mortality in patients undergoing hemodialysis
por: Mori, Katsuhito, et al.
Publicado: (2019)

Possible role of insulin resistance in activation of plasma xanthine oxidoreductase in health check-up examinees
por: Kurajoh, Masafumi, et al.
Publicado: (2022)

Association of plasma xanthine oxidoreductase activity with vascular endothelial function independent of serum uric acid level: MedCity21 health examination registry
por: Kurajoh, Masafumi, et al.
Publicado: (2023)

Insulin Resistance Associated with Plasma Xanthine Oxidoreductase Activity Independent of Visceral Adiposity and Adiponectin Level: MedCity21 Health Examination Registry
por: Kurajoh, Masafumi, et al.
Publicado: (2019)

Uric acid shown to contribute to increased oxidative stress level independent of xanthine oxidoreductase activity in MedCity21 health examination registry
por: Kurajoh, Masafumi, et al.
Publicado: (2021)

Association between Levocarnitine Treatment and the Change in Knee Extensor Strength in Patients Undergoing Hemodialysis: A Post-Hoc Analysis of the Osaka Dialysis Complication Study (ODCS)
por: Matsufuji, Shota, et al.
Publicado: (2022)

Association of plasma xanthine oxidoreductase activity with blood pressure affected by oxidative stress level: MedCity21 health examination registry
por: Yoshida, Shio, et al.
Publicado: (2020)

Maintenance of Skeletal Muscle to Counteract Sarcopenia in Patients with Advanced Chronic Kidney Disease and Especially Those Undergoing Hemodialysis
por: Mori, Katsuhito
Publicado: (2021)

Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis
por: Ichii, Mitsuru, et al.
Publicado: (2021)

Sarcopenia and osteosarcopenia among patients undergoing hemodialysis
por: Xiang, Ting, et al.
Publicado: (2023)

High prevalence of sarcopenia and myosteatosis in patients undergoing hemodialysis
por: Fu, Chen, et al.
Publicado: (2023)

Association of Reduced Free T3 to Free T4 Ratio with Lower Serum Creatinine in Japanese Hemodialysis Patients
por: Inaba, Masaaki, et al.
Publicado: (2021)

Reduced Risk of Progression from Non-Severe to Severe COVID-19 in Hospitalized Dialysis Patients by Full COVID-19 Vaccination
por: Ichii, Mitsuru, et al.
Publicado: (2022)

Low Free Triiodothyronine Level as a Predictor of Cardiovascular Events and All-Cause Mortality in Patients Undergoing Hemodialysis: The DREAM Cohort
por: Yamazaki, Yuko, et al.
Publicado: (2021)

Linagliptin monotherapy compared with voglibose monotherapy in patients with type 2 diabetes undergoing hemodialysis: a 12-week randomized trial
por: Mori, Katsuhito, et al.
Publicado: (2016)

Associations of Serum Insulin-Like Growth Factor 1 with New Cardiovascular Events and Subsequent Death in Hemodialysis Patients: The DREAM Cohort
por: Nakaya, Rino, et al.
Publicado: (2022)

Is sarcopenia a real risk factor for mortality in patients undergoing hemodialysis?
por: Bae, Eun Hui
Publicado: (2019)

Pro-Aging Effects of Xanthine Oxidoreductase Products
por: Battelli, Maria Giulia, et al.
Publicado: (2020)

Xanthine oxidoreductase activity is correlated with hepatic steatosis
por: Yagi, Chisako, et al.
Publicado: (2022)

Discriminating Susceptibility of Xanthine Oxidoreductase Family to Metals
por: Steunou, Anne-Soisig, et al.
Publicado: (2023)

Mutations Associated with Functional Disorder of Xanthine Oxidoreductase and Hereditary Xanthinuria in Humans
por: Ichida, Kimiyoshi, et al.
Publicado: (2012)

Plasma Xanthine Oxidoreductase (XOR) Activity in Cardiovascular Disease Outpatients
por: Matsushita, Masato, et al.
Publicado: (2020)

Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview
por: Chen, Changyi, et al.
Publicado: (2016)

The Role of Oxidative Stress in Hyperuricemia and Xanthine Oxidoreductase (XOR) Inhibitors
por: Liu, Ning, et al.
Publicado: (2021)

Sarcopenia and Mortality in Older Hemodialysis Patients
por: Sánchez-Tocino, M. Luz, et al.
Publicado: (2022)

Evaluation of Neuronal Protective Effects of Xanthine Oxidoreductase Inhibitors on Severe Whole-brain Ischemia in Mouse Model and Analysis of Xanthine Oxidoreductase Activity in the Mouse Brain
por: SUZUKI, Go, et al.
Publicado: (2015)

Impact of sarcopenia on long-term mortality and cardiovascular events in patients undergoing hemodialysis
por: Kim, Jwa-Kyung, et al.
Publicado: (2019)

Cardiothoracic Ratio as a Predictor of Cardiovascular Events in a Cohort of Hemodialysis Patients
por: Okute, Yujiro, et al.
Publicado: (2017)

Metabolic syndrome and cancer risk: The role of xanthine oxidoreductase
por: Battelli, Maria Giulia, et al.
Publicado: (2018)

Xanthine oxidoreductase: One enzyme for multiple physiological tasks
por: Bortolotti, Massimo, et al.
Publicado: (2021)

Gender Differences in the Impact of Plasma Xanthine Oxidoreductase Activity on Coronary Artery Spasm
por: Watanabe, Ken, et al.
Publicado: (2021)

Characterization of the gut microbiota in hemodialysis patients with sarcopenia
por: Zhou, Qifan, et al.
Publicado: (2021)

Sarcopenia and echocardiographic parameters for prediction of cardiovascular events and mortality in patients undergoing maintenance hemodialysis
por: Zhang, Mengyan, et al.
Publicado: (2022)

Chemical Nature and Reaction Mechanisms of the Molybdenum Cofactor of Xanthine Oxidoreductase
por: Okamoto, Ken, et al.
Publicado: (2013)

Xanthine oxidoreductase in cancer: more than a differentiation marker
por: Battelli, Maria Giulia, et al.
Publicado: (2015)

Xanthine Oxidoreductase-Derived Reactive Species: Physiological and Pathological Effects
por: Battelli, Maria Giulia, et al.
Publicado: (2016)

Xanthine oxidoreductase: A leading actor in cardiovascular disease drama
por: Polito, Letizia, et al.
Publicado: (2021)

Allopurinol and oxypurinol differ in their strength and mechanisms of inhibition of xanthine oxidoreductase
por: Sekine, Mai, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ge1g0k1f4sgmvejt3og13rudka